Inventor · disambiguated record
Joshua D. Waetzig
Also filed as: WAETZIG JOSHUA · WAETZIG JOSHUA D
5 granted patents·6 pending applications·8 citations·filing 2020–2023
72Inventor score
Top patents by PatentIndex Score
11 records- 0194US11767330B2Citrate salt, pharmaceutical compositions, and methods of making and using the sameFOGHORN THERAPEUTICS INC·Filed 2022·Granted Sep 26, 2023·5 cites·12 claims
- 0291US11999744B2Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of makingBLUEPRINT MEDICINES CORP·Filed 2023·Granted Jun 4, 2024·2 cites·14 claims
- 0384US12060354B2Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of makingBLUEPRINT MEDICINES CORP·Filed 2021·Granted Aug 13, 2024·1 cites·14 claims
- 0478US11964980B2Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1- f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of makingBLUEPRINT MEDICINES CORP·Filed 2022·Granted Apr 23, 2024·0 cites·7 claims
- 0562US2024190894A1Citrate salt, pharmaceutical compositions, and methods of making and using the sameFOGHORN THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0656US2025085300A1Stability-enhancing compositions and methods of preparing compoundsFOGHORN THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 0756US2024300922A1Process for preparing egfr inhibitorsBLUEPRINT MEDICINES CORP·Filed 2022·Application pending·0 cites
- 0854US12448366B2Solid forms of pralsetinibRIGEL PHARMACEUTICALS INC·Filed 2021·Granted Oct 21, 2025·0 cites·19 claims
- 0952US2024059672A1Method of preparing pralsetinibBLUEPRINT MEDICINES CORP·Filed 2021·Application pending·0 cites
- 1050US2023203009A1Pralsetinib pharmaceutical compositionsBLUEPRINT MEDICINES CORP·Filed 2021·Application pending·0 cites
- 1147US2022281879A1Salt and crystal forms of an activin receptor-like kinase inhibitorBLUEPRINT MEDICINES CORP·Filed 2020·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →